Belatacept: Better Outcomes, no Cancer Signal, but Limited Global Access.

Nulojix (belatacept) - BMS

Belatacept: Better Outcomes, no Cancer Signal, but Limited Global Access. (PubMed, Transplantation) - Sep 10, 2026 - No abstract available
Journal • Oncology

http://www.ncbi.nlm.nih.gov/pubmed/42715289

Fabian Halleck; Klemens Budde; Stefan Reuter

Sep 10, 2026